257 related articles for article (PubMed ID: 22105894)
1. Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients.
Kanda T; Nishida T; Wada N; Kobayashi O; Yamamoto M; Sawaki A; Boku N; Koseki M; Doi T; Toh Y; Kakeji Y; Sugiyama T; Komatsu Y; Kikuchi S; Ogoshi K; Katai H; Miyachi K; Hirota S; Ohtsu A
Int J Clin Oncol; 2013 Feb; 18(1):38-45. PubMed ID: 22105894
[TBL] [Abstract][Full Text] [Related]
2. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.
Dematteo RP; Ballman KV; Antonescu CR; Maki RG; Pisters PW; Demetri GD; Blackstein ME; Blanke CD; von Mehren M; Brennan MF; Patel S; McCarter MD; Polikoff JA; Tan BR; Owzar K;
Lancet; 2009 Mar; 373(9669):1097-104. PubMed ID: 19303137
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202).
Nishida T; Shirao K; Sawaki A; Koseki M; Okamura T; Ohtsu A; Sugiyama T; Miyakawa K; Hirota S
Int J Clin Oncol; 2008 Jun; 13(3):244-51. PubMed ID: 18553235
[TBL] [Abstract][Full Text] [Related]
5. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
Du CY; Zhou Y; Song C; Wang YP; Jie ZG; He YL; Liang XB; Cao H; Yan ZS; Shi YQ
Eur J Cancer; 2014 Jul; 50(10):1772-1778. PubMed ID: 24768330
[TBL] [Abstract][Full Text] [Related]
6. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.
Kang YK; Ryu MH; Yoo C; Ryoo BY; Kim HJ; Lee JJ; Nam BH; Ramaiya N; Jagannathan J; Demetri GD
Lancet Oncol; 2013 Nov; 14(12):1175-82. PubMed ID: 24140183
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management.
Joensuu H
Drugs; 2012 Oct; 72(15):1953-63. PubMed ID: 22994537
[TBL] [Abstract][Full Text] [Related]
8. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome.
Zhu J; Yang Y; Zhou L; Jiang M; Hou M
BMC Cancer; 2010 May; 10():199. PubMed ID: 20465813
[TBL] [Abstract][Full Text] [Related]
9. Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial.
Blay JY; Shen L; Kang YK; Rutkowski P; Qin S; Nosov D; Wan D; Trent J; Srimuninnimit V; Pápai Z; Le Cesne A; Novick S; Taningco L; Mo S; Green S; Reichardt P; Demetri GD
Lancet Oncol; 2015 May; 16(5):550-60. PubMed ID: 25882987
[TBL] [Abstract][Full Text] [Related]
10. Approval summary: imatinib mesylate for one or three years in the adjuvant treatment of gastrointestinal stromal tumors.
Cohen MH; Johnson JR; Justice R; Pazdur R
Oncologist; 2012; 17(7):992-7. PubMed ID: 22643537
[TBL] [Abstract][Full Text] [Related]
11. Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors.
Cohen MH; Cortazar P; Justice R; Pazdur R
Oncologist; 2010; 15(3):300-7. PubMed ID: 20200041
[TBL] [Abstract][Full Text] [Related]
12. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor.
Li J; Gong JF; Wu AW; Shen L
Eur J Surg Oncol; 2011 Apr; 37(4):319-24. PubMed ID: 21277730
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib.
Joensuu H; Eriksson M; Hall KS; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Ballman KV; Leinonen M; DeMatteo RP; Reichardt P
Cancer; 2014 Aug; 120(15):2325-33. PubMed ID: 24737415
[TBL] [Abstract][Full Text] [Related]
14. [Indications for pre- and postoperative treatment with imatinib for gastrointestinal stromal tumors].
Heger U; Weitz J; Lordick F
Chirurg; 2008 Jul; 79(7):630-7. PubMed ID: 18548219
[TBL] [Abstract][Full Text] [Related]
15. Prospective observational study of imatinib therapy in Japanese patients with advanced gastrointestinal stromal tumors: long-term follow-up and second malignancy.
Kanda T; Ishikawa T; Hirota S; Yajima K; Kosugi S; Ohashi M; Suzuki S; Mashima Y; Ajioka Y; Hatakeyama K
Jpn J Clin Oncol; 2012 Jul; 42(7):578-85. PubMed ID: 22523393
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
Raut CP; Espat NJ; Maki RG; Araujo DM; Trent J; Williams TF; Purkayastha DD; DeMatteo RP
JAMA Oncol; 2018 Dec; 4(12):e184060. PubMed ID: 30383140
[TBL] [Abstract][Full Text] [Related]
17. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.
DeMatteo RP; Ballman KV; Antonescu CR; Corless C; Kolesnikova V; von Mehren M; McCarter MD; Norton J; Maki RG; Pisters PW; Demetri GD; Brennan MF; Owzar K;
Ann Surg; 2013 Sep; 258(3):422-9. PubMed ID: 23860199
[TBL] [Abstract][Full Text] [Related]
18. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.
Corless CL; Ballman KV; Antonescu CR; Kolesnikova V; Maki RG; Pisters PW; Blackstein ME; Blanke CD; Demetri GD; Heinrich MC; von Mehren M; Patel S; McCarter MD; Owzar K; DeMatteo RP
J Clin Oncol; 2014 May; 32(15):1563-70. PubMed ID: 24638003
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors.
Yoo C; Ryu MH; Ryoo BY; Beck MY; Kang YK
Invest New Drugs; 2013 Oct; 31(5):1367-74. PubMed ID: 23591629
[TBL] [Abstract][Full Text] [Related]
20. Imatinib (Glivec) and gastrointestinal stromal tumours in Nigerians.
Durosinmi MA; Salawu L; Lawal OO; Ojo OS; Alatishe OI; Oyekunle AA; Bolarinwa RA; Adisa AO; Badmos K; Anomneze EE; Ayansanwo AO
Afr J Med Med Sci; 2013 Dec; 42(4):325-32. PubMed ID: 24839736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]